Animalcare Group PLC
LSE:ANCR
Animalcare Group PLC
Animalcare Group Plc engages in the development, sale, and supply of generic veterinary medicines and animal identification products. The company is headquartered in Ripon, North Yorkshire. The company went IPO on 2008-01-15. The firm is focused on developing and commercializing prescription and over-the-counter pharmaceutical products. The firm operates in three categories within the veterinary market, which includes Companion Animals, Equine and Production Animals. The company manages international supply chain, including specialist veterinary wholesalers and distributors. The firm develops, supplies and markets products and services to the veterinary profession. The company focuses on therapeutic areas, which includes pain management, dermatology and anti-infectives. The Company’s product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs.
Animalcare Group Plc engages in the development, sale, and supply of generic veterinary medicines and animal identification products. The company is headquartered in Ripon, North Yorkshire. The company went IPO on 2008-01-15. The firm is focused on developing and commercializing prescription and over-the-counter pharmaceutical products. The firm operates in three categories within the veterinary market, which includes Companion Animals, Equine and Production Animals. The company manages international supply chain, including specialist veterinary wholesalers and distributors. The firm develops, supplies and markets products and services to the veterinary profession. The company focuses on therapeutic areas, which includes pain management, dermatology and anti-infectives. The Company’s product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs.
Revenue Growth: Animalcare Group delivered a strong half year with revenue up 18.3%, driven largely by the Randlab acquisition.
Randlab Acquisition: Randlab has integrated well, delivered 14% growth, and contributed high-margin sales in line with expectations.
Margin Expansion: Gross margin benefited from Randlab’s portfolio, with Randlab delivering 73% gross margin and EBITDA up 47%.
Organic Growth: Organic revenue growth was about 1%, held back by FX headwinds and the Conofite product issue in Spain.
Cash Generation: Cash conversion reached 70% at the half year, with free cash flow of GBP 4.3 million, supporting ongoing investment.
R&D Investment: Significant increase in R&D spend to around 5% of revenue, aiming to build a pipeline of higher value, innovative products.
M&A Firepower: The balance sheet remains strong after the Randlab deal, with GBP 20–25 million available for further acquisitions.
Key Product Updates: Daxocox and Plaqtiv are showing strong growth and are expected to drive future organic performance.
